Welcome to the Corbion Q3 Results 2024 on October 29, 2024. During the introduction, all participants will be in a listen-only mode. After that, there'll be an opportunity for questions. If any participant would like to ask a question, please press star one one on your telephone. Please note that this call will be recorded. I would now like to hand over to Mr. Alex Sokolowski, Head of Investor Relations. Please go ahead, sir. Good morning, and welcome to the Corbion third quarter 2024 conference call. This morning, we published our Q3 and year-to-date results, and the press release and presentation can be found on our website, www.corbion.com, Investor Relations, Financial Publications. Before we begin, please note that today's discussion will include forward-looking statements based on current expectations and assumptions. These statements involve risks and uncertainties that may cause actual results to differ materially from those expressed. Factors beyond our control, including market conditions, economic changes, and regulatory actions, can impact outcomes. Corbion does not undertake any obligation to update statements made in this call or contained in today's press release and presentation. For more details on our assumptions and estimates, please refer to our annual reports. I'm Alex Sokolowski, Head of IR, and with me on the call today are Olivier Rigaud, Chief Executive Officer, and Peter Kazius, Chief Financial Officer. Now, I would like to hand the call over to Olivier. Olivier? Thank you, Alex, and good morning, everyone. Welcome to Corbion's Q3 and year-to-date results 2024. Starting now with the key highlights. I'm pleased to report that our company continues to deliver outstanding results, achieving accelerated organic sales growth of 2.6%, bringing sales for the first nine months of the year to 973 million EUR. We saw a solid volume mix growth of 6.1% for the first nine months, driven by an outstanding Q3 with volume mix of 11.1%. We reached an Adjusted EBITDA of 135.7 million EUR, with Q3 alone contributing 49.6 million EUR. In Functional Ingredients & Solutions, we continue to perform with positive volume mix growth, particularly driven by a strong demand in our specialty ingredients, both in natural preservation and in our functional systems, while the softness in some biochemical markets persists. We are pleased to see continued growth in our product market adjacencies like dairy stabilizers, natural antioxidants, and natural mold inhibitors. Lactic acid volume through the PLA joint venture have grown both in year to date and Q3. The sales of the joint venture grew 16% organically, driven by volume. Likewise, in our Health & Nutrition segment, we achieved strong double-digit growth, both sales and adjusted EBITDA, primarily driven by the Nutrition segment, containing our algae fermentation products, Omega-3 DHA. In Q3, we've seen double-digit growth in all our segments: Nutrition, Biomedical Polymers, and Pharma. On the financial front, I'm pleased to report a free cash flow of EUR 50.8 million, excluding divestment proceeds. This strong cash generation underlines our commitment to financial discipline and operational excellence. Our restructuring plan is right on track, and I'm confident that it will continue to drive efficiency and profitability in the quarters ahead. Now, looking forward, today, we upgraded our full-year 2024 outlook, whereas previously we guided for full-year 2024 volume mix growth of 2-6%, we now guide for above 5%. Our previous Adjusted EBITDA organic growth guidance was for more than 18%, and we upgrade that to 22-25%. Also, we upgrade our free cash flow from above EUR 50 million by around EUR 10 million to more than EUR 60 million at year-end. Our performance this quarter reflects the dedication and execution power of our team, the strength of our strategy, and the confidence we have in delivering value to all of our stakeholders. That concludes our prepared remarks, and thank you for the attention. Peter and I will be happy to take your questions. Alex, let's start the Q&A now. Sure. Thank you, Olivier. Call participants, if you'd like to ask a question on the call this morning, please press star one on your telephone. Star one one, sorry, on your telephone, and you'll be placed in the queue. Our first question this morning comes from Setu Sharda from Barclays. Setu, please go ahead. Hi, thanks for taking my question. I have three questions. The first is on the food ingredients and solutions volume. The volume step up was quite impressive and implies around double-digit food ingredients volume growth, despite underlying end market was weak. So how sustainable is this growth? And on the flip side, like, the pricing was around 5% lower, so is this the function of input cost, or are you seeing increased competition in this space? And what is the impact on margins due to this price cut? My second question is on health and nutrition margins, which have sequentially ticked down despite strong volume growth. What is the delta here? And also, as you mentioned, some contracts are multi-year. Can you quantify how much is the multi-year, and what is the percentage of spot, which may be more sensitive to wild fish oil price dynamics? And my third question is around PLA JV. If the margin pressure is sustained, will the JV continue to produce at full capacity? And what happens to the JV's lactic acid demand from Corbion? Any risk of overcapacity there? And a related question, like, if you can remind us how much of functional ingredient and solution lactic acid volume is currently going to JV? Thanks. Okay, thanks, Setu. I will answer the first one, on the food, food ingredient solution, and Peter will take the margin inflation, and then we come back on the JV, later. So first question around the volume in food ingredient. We see already since a few quarters a very good recovery. If you remember, we are trailing negative last year, and we came really close to breakeven, you know, in Q1 this year, and we upgraded in Q2 and have even a stronger Q3 now. We see this momentum in food continuing. This is quite nicely spread. Obviously, as you know, our major markets for food ingredients are primarily in the U.S. and Latin America. These are the two strong regions for us. But we see good signals coming from the market with a good pipeline, so we do not expect this to reverse. If you go to pricing, which was the other underlying questions there, obviously, we've seen relaxation early this year, related to input costs that we have to partially give back to the market. You know, we've seen that, you know, price impact lowering, you know, on the second half of the year. Now, as we speak, we are getting to the price round for 2025. What we see, it's always a bit the same is, of course, with a less differentiated product, a plain lactic acid, there is more competition than in more sophisticated derivatives or we have high degree of differentiation. So obviously, the competition is more intense on basic lactic acid, you know, that go to more commoditized market, and a lot less in the other segments. So, so on the, let's say, piece you mentioned, on biochemicals, when we express, also to see some softness, we speak primarily about two sub-segments, one being electronics and the other being agrochemicals. Electronics, we mentioned that already for a while. It's not a huge business for us, but it's a profitable one. We've been down the cycle actually already for almost a year and a half now. Most of the end players were assuming, you know, back to growth in the H2 this year, which now they mention more 2025. We've not seen any recovery yet, except, you know, and this is very fresh, we start to see some better momentum, as from October now in Q4, but it's still very soft. I would not bank on the fact that, yeah, we've turned necessarily the corner in electronics, there. But this is the major part, you know, I'd like to mention into this, biochemicals business. So, just going back to also your question on the JV, on the lactic demand, to also answer that point as we are on this. In the Functional Ingredients & Solutions, we basically account, you know, the sales of the lactic acid to the JV, which, you know, is really a longer term agreement. We have with the JV, with the price formula, we have passed through on input costs and energy. So, and, yeah, this fluctuates of course with the volume, you know, but it has been, you know, in the lower EUR 60 million sales per year on the total EUR 1 billion sales of the FIS business unit. So it's not a massive amount, as you can see. Of course, as we are ramping up the, the JV is ramping up sales, this number gonna increase. But, you know, we do not expect this to also become. If you make the math, you know, something ostensibly above the 100 million mark in terms of business. Now, I will hand over to Peter on the H&N margin and the PLA margin. So, Setu, thanks for the questions. I mean, let's first do the health and nutrition margin, and also your question about the longer term contracts. As indicated earlier, we have some longer contracts in the Algae part of the business or the nutrition part of the business. Think about two to three years going forward, locked at fixed prices. If you look to the margin profile, then Q3 is indeed mildly lower than Q2. By the way, it's higher than the Q1 elements, and it's really driven by mixing our portfolio. And mixing our portfolio is two elements. It's customer mix in some of the segments, which is one, and it's also, if you look to the phenomenal growth in Q3 itself, it's driven by Algae, which is having a nice margin, but a bit lower than the biomedical part. It's also good to know that in Q3 itself, all the sub-segments in this business are nutrition, biomedical, polymer, and pharma really delivered outstanding double-digit growth from that perspective. If I then go back to PLA and the margin in the joint venture itself, then indeed volumes are up, sales is also up. But if you look to the combination of sales, then pricing is indeed lower, also lower than historically, and therefore the margin in this quarter is 4.5% in terms of EBITDA. With the visibility we currently have, we don't see this going up significantly to the double-digit levels in the coming quarters. And this is really driven by the pricing momentum in the PLA business itself. Okay, thank you. I hope that answers the question. That's quite helpful. Yeah, yeah, thank you. That's quite helpful, yeah. Okay, thank you. Our next question this morning comes from Wim Hoste of KBC Securities. Wim, please go ahead. Yes, thank you and good morning to all. I wanted to dig a little bit further into the full year guidance, which was upgraded, so if you look at the EBITDA comments. But if you look what is implied in the new guidance, it is basically a Q4 that is yeah bumping around similar level as the Q4 2023 numbers. So I was wondering what makes you cautious given that yeah there was phenomenal growth in three or four more than 40% on the EBITDA and then just a flattish kind of Q4 guidance seems cautious. So if you can elaborate on the reasons for that. And then I just wanted to also dig, and maybe that's related into the cost elements going forward for Q4, sugar, freight, things like that. So that would also be interesting. And then a final question would be the joint venture, if I can come back to the margin pressure. Is that margin pressure that we see in Q3 due to previous longer term contracts that are maturing and cannot be renewed at the old kind of pricing? Or is that just a reflection of increased pricing pressure that you're now starting to see in the market, and then that will continue going forward? So if you can elaborate a little bit more, that would also be helpful. Thank you. Okay. Thanks, Wim, and, I'll let Peter answer the first two, and I will, maybe comment also on market developments on PLA, later. So Wim, you're right, that if you look year to date, our organic growth is 28.7%. And in the full year, we guided mildly lower, so that means a lower growth rate in Q4. I think a couple of things to note there. One is, and that is more in the absolute amount, is that the absolute sales level in Q4 is normally lower driven by seasonality. The other one is a bit in phasing, as we indicated, in health and nutrition. Health and nutrition, super strong growth in Q3. And we see a bit of phasing impact with Q4 as well. I mean, if you combine them both, really on track with a bit of phasing impact in that one. Then, and this is a temporary phenomenon which is impacting Q3 and also a bit in Q4, is that our freight rates went up really, the Thailand Europe in the middle of the year. And then normally in the P&L, it's having a bit of delay impact impacting Q3 and a bit of Q4. And the other one is really a bit of phasing impact in the cost structure, both in Q4 last year as well as in Q4 this year. So overall, I would say nothing to worry on that perspective. So those were the two indeed. I hope that- Mm-hmm. Yeah. On the JV margin, Wim, so, couple of additions there. So, on your first question, is that coming from a long-term contract maturing? The answer is not necessarily. We have a few longer term agreement that indeed are quite protective right now as we speak. What's happening in terms of basically also geographical mix, we said it last time, but actually, most of the growth is coming today from Asia and particularly China, where prices are lower than in other regions, so primarily Europe or the U.S. And what is really pulling demand, and it's a confirmation of what we said in Q2 today, is primarily Asia and mostly China, where their competition is present, but not just on PLA, as well in some more traditional polymers, you know, we are fighting against being a polystyrene primarily. So what we've seen, what the joint venture has seen is indeed because of their geographical mix and generating most of the growth from China, overall price erosion that is impacting their profitability at a time where also, you know, we as Corbion are passing through increased input cost with some delays, so they are indeed also having their lactic acid price reflecting, you know, the higher input costs we've seen over the last month. So that's a second driver, but it's primarily price. Now, l et me also expand a bit on the outlook. What we see is indeed the volume is getting healthier, and if you look to the momentum, we are getting, of course, a better, although exposed to China, and we anticipate the same for next year. So when we look to the joint venture forecast for next year, there is further volume increase, you know, next year, with the same drivers. Yeah, so still very much loaded into Asia and China. So that means also we do not expect a massive turnaround into the JV margin over the next quarters. Okay, understood. That's very clear. Thank you. All right, thank you. Our next question this morning comes from Fernand de Boer from Degroof Petercam. Ferdinand? Yes, good morning. It's Fernand de Boer from Degroof Petercam. A couple of questions on my side. First, on the pricing in health and nutrition, more than some 8% this quarter, a big step up from the previous quarter. Could you elaborate a little bit on what's behind that? That's the first question, and then maybe coming back on the outlook, but not so much for 2024 as more for 2025. At your capital markets day, you guided for an EBITDA of, I think, EUR 225 million. I think there is still maybe some 12 million to run-rate cost left for next year, so that would mean EUR 213 million for 2025. Are you still comfortable with that one? Okay. Let me pick the both questions, Fernand. So in health and nutrition, you're right, that if you look to the pricing momentum in terms of percentage over last year, it is an increase. This is a reflection, it's a bit technical, of the price increase we did earlier in the year, which in H1 mainly came into volume mix, because we changed basically our product content with DHA in the middle of last year. So it's more a shift, I would say, from the mix element to the pricing element. So the majority of this 8% is price increase within Algae, starting already earlier this year. If you look to the pricing during the quarters, it's relatively constant. If you look to 2025, there we're still confident that we deliver the numbers for the year 2025. I mean, we're currently in a more detailed budget process, and then provide guidance how we normally do it in Q1 next year. But in terms of the programs we articulated to offset this trend, of course, we are on track. Maybe, maybe one also last question. Technically, maybe, you up your guidance for free cash flow, but at the same time, and you also up your guidance for your EBITDA growth, so I think that that goes hand in hand, but then at the same time, your leverage guidance is actually narrowed to the high end of the range, where you should expect that that should come down to the low end of the range. Could you explain that? Yeah, no, I can explain that. So we indeed narrowed the guidance where we currently are, while increasing the free cash flow guidance and indeed the EBITDA. I think the key element of that one is also the share buyback which we did of EUR 20 million. This is having a 0.15 in the overall one. So we were quite confident we stayed within the range with all the different indicators. But that is, I think, the key one if you compare it with the original guidance which we had earlier this year. If you currently see where we are, I mean, then we reduce the bandwidth from that perspective. But, the share buyback, you already knew at the half-year figures. Yeah, and we did not narrow the guidance at that moment in time. That's correct. Okay, but it's not that because of Forex movement that at the end of the day the higher the net debt will be higher? No, if you look to it, there is no significant Forex impact. Free cash flow is perfectly on track what we thought, and so the answer is no from that perspective. Also, if you look to Forex and the majority in terms of net debt is U.S. dollar related, the U.S. dollar is relatively stable. I mean, in Q3, we saw a bit up and up and down or down and up, depends a bit how you look, but there is no significant impact in that one. Okay. Thank you very much. Okay, thank you, Fernand. Our next question comes from Sebastian Bray from Berenberg. Sebastian, please go ahead. Hello, hello, good morning, and thank you for taking my questions. I'll start with the PLA joint venture, please. Can you remind me of the net debt of this JV? Because from memory, there was something like EUR 100 million associated with it, and if the EBITDA run rate currently is something like EUR 2 million on a quarterly basis, is there any risk of this running into problems with covenants? I'm not entirely sure if that net debt figure is correct, but I just want to have a think about its leverage position. That's my first question. Oh, I thought I'd wait for the second, but I will take this one, Sebastian. So, there's no risk in terms of covenant with the joint venture itself. If you look to the financing situation of the PLA joint venture, then you're right that the joint venture is 50-50 financed by both parents. Now, that means both TotalEnergies as well as Corbion. And there is, indeed, around EUR 60 million loan on our balance sheet, as well as an equity stake of around 30. So the numbers are indeed correct. You're right, that if you look to the joint venture itself with the EBITDA level currently, then there is no, yeah, there's no risk in terms of this element. Is the joint venture covering its interest charges, or is it burning cash at the current level of profitability? No. So if you-- we still ambitions to get the interest basically out of the joint venture. That's helpful. Thank you. Can I ask a more philosophical question about PLA? Are you in this business because you want to be, or are you in this business because you feel you have to be, as it's a large offtake from the Thai plant, the 125 kiloton lactic acid facility brought online a few quarters ago? I think it's, it's indeed a very high, philosophical question, Sebastian. If I may, if you look again into how the market of lactic acid is being split, before the PLA market cracked down, you know, lactic to PLA came to roughly 40% of the lactic acid, you know, market potential. It has reduced a bit in between, but, you know, all indicators shows that midterm, this is getting back up. So, for us, I think, at that time when we developed PLA as another derivative, that was the aim, to find as many outlets and how we would play, in there. It is indeed a very nice plant filler for the Thai capacity. As you know, you make really your profit running at max capacity, and we see ultimately, you know, this as a very nice addition to what is the largest lactic plant in the world. If you think once we have, you know, all capacity fully occupied, and the JV is really, I think, a best way for us to constantly max out the throughput of that plant. Now, what we made clear in the last capital market update is that, yeah, we will not build any further lactic acid capacity to accommodate, you know, the PLA market. This is not what we are in. But I think this JV on the site with another diverse supply is the right thing for this large lactic acid site. But this is where we would, for the time being, you know, really stop. That's helpful. Thank you. My last one is on the algae business. How are the efforts to enter the human nutrition market again going in this business? And the reason that I ask is my suspicion is there's not a lot more volume left to grow with existing capacity for '25, and that means the earnings growth is a function of two things, assuming constant raw materials in that year. One is mix, and the second is price. My feeling is that your company probably doesn't have that much more scope to push prices in the year, and that leaves mix as the swing factor. From memory, Corbion tried once and failed to establish itself in human nutrition. Why would this time be different for algae? If you look at our approach in human nutrition, as we discussed before, you know, we are well ahead in the journey of this investment of 50 million EUR, where a big part of this investment in a Brazilian plant is to upgrade the mix to be able to supply the human nutrition market, as it requires different, you know, purification and type of omega-3s. We are really well ahead, basically, because we've had already a pilot productions to reference the product across the market globally. We kicked that off already, you know, early this summer, last summer, getting approval. But basically, it's about really getting that additional capability and capacity in the plant that we've built with this investment, which we aim to complete early 2025. Now, back to indeed, I don't know what happened in the past in human nutrition, but you know, having run myself the JV between Naturex and Aker BioMarine on omega-3 in the past, you know, the omega-3 market in human is primarily a U.S. market. This is where the big size of the price is. And we don't go directly to the end user. You have to go through the people that basically are the key players to supply the vitamin shops, the GNCs, the Holland & Barretts of this world. So we've built relationship with all these players so far, so we are really confident that, you know, we're gonna get some breakthrough in 2025. So that's we are working on. That's helpful. Thank you for taking my questions. Okay. Our next question this morning comes from Robert Jan Vos from ABN AMRO ODDO BHF. Robert Jan, go ahead. Yes, thank you. Hi, good morning, all. I have a couple of questions left. First on the PLA joint venture, if I'm not mistaken, you reported the lowest quarter EBITDA margin for the JV this quarter since at least 2019. I would assume that you're probably not in this business for an EBITDA margin of 4.5%, and it also does not seem to be short-term issue, considering your outlook. So my question is, what could be the strategic implications for the JV of this current and also continuing sluggish performance? That's my first question. Yeah, Robert Jan, if I can take this one. Basically, when we look at it, and you know, obviously, I think there is high visibility on the joint venture performance, don't get me wrong, but, you know, we are primarily, and the corporate members do sell lactic acid to the JV, and this is what is being consolidated in our number, and this is where, you know, we want to make sure we get the volume at the right price for us, because it's a very interesting deal we have, which is another defense supply. Now, back to the more strategic questions, it's a bit premature to answer as, you know, the '25 is the last year of Advance 2025, the strategic period. We are planning to get into a new strategic review next year, so for sure we're gonna come back to the market by the end of next year with, you know, whatever we're gonna come back with at that time. And obviously, part of the exercise is to review the entire portfolio. Yeah. Okay, that's very clear. Then my second question, maybe a bit of clarification on the guidance that you provided at CMD. Ferdinand already alluded to this, but in this presentation, you provided an EBITDA guidance in a range of 217-236, midpoint being 226. I always understood that the costs related to the disposed emulsifier business would have been fully absorbed. So isn't it so that this guidance range does not change in the new setting? Maybe, Peter, you can answer this question, 'cause I- Yeah- I was not aware that the... Yeah, go ahead, sorry. Oh, so happy to answer this one, Robert Jan. So, yes, you're absolutely right from that perspective. So what we guided to was, at that moment in the quarter, this 15%-20% range, then you come to this number. And the plan is to fully offset these stranded costs by the actions we also discussed basically earlier in the call. So from that perspective, it's the result of Q3 is not impacting anything for the outlook 2025. So the midpoint of that range is still 226, and you just confirmed that you still think that it is feasible to achieve that in 2025? Correct. Correct. Okay, that is also very clear. Thank you. And maybe also a question, clarification question: In the paragraph on health and nutrition, you guide for lower growth in Q4. I assume high single digits you mentioned. I assume that that is meant for the whole division, or was this comment just for the nutrition segment within the division? This comment is meant for the whole division, health and nutrition, because normally we don't guide on specific elements within health and nutrition. Read this as for the whole health and nutrition part of the portfolio. Okay. Again, very clear. Thank you. Okay, thank you. Our next question this morning comes from Karel Zoete from Kepler Cheuvreux. Karel, please go ahead. Yes, thanks. Good morning, all. I have two questions. The first one is on the progress with the fixed cost savings program. Can you update us where we stand? I think early June, there have been some progress there. What's happened since? The second question is on the volume leverage within the functional ingredients and solutions business. Has very strong volume growth, still margins stable-ish quarter on quarter. You mentioned you took some costs in there as well. So if you can speak a bit about volume leverage. And maybe then a final question is you highlighted the new factory in Thailand is performing well. When it comes to the benefits of this to the bottom line, is this more a 2025 impact, or are we starting to see somewhat of an effect already? Thank you. Let me pick them. Thanks for the questions, Karel. So in terms of... let me start with fixed cost. That's progressing well. As we indicated in H1, we reduced already 130 FTEs during the course of H1. And we then planned to do a sequential one during the course of Q3, which we also did. And one of the other exercises which we indicated was the mothballing of Peoria. So well on track from that perspective. If you look on Thailand, then you're right, as we always indicated, that the new factory and the impact in terms of the bottom line improvement really anticipated to be in 2025. And the one on volume leverage, it depends always a bit when you look quarter over quarter, year over year. So in terms of if you look to the absolute sales levels, Q2, Q3 they are around at the same level from that perspective. So then quarter over quarter, there's kind of a minimal volume leverage. And you're also right that as we indicated in H2, that sugar prices are on the downward journey, meaning Q3 being lower than Q2, with an offset of this freight rate. And this freight rate, we also see a bit in Q4, and then it should normally or fully kind of normalize later on the quarter after the quarter after that. So that gives you a bit of the dynamic overall of the margin development. Thank you. And if I may, can I ask one follow-up question? You already mentioned the, you had a stranded cost, and the projects there being on track. Can you go over some of the major projects that should support the P&L next year, where you already made clear plans or see initial progress? Yeah, Karel, I can take this one. Basically, we have big projects around the product portfolio rationalization. So basically we look at, you know, the, as usual, the tail. SKU simplification is another. That goes closely together, so we're, we are reviewing also all that and the benefit associated, to that. We are also having a very, deep approach to procurement, and we've been working also with external support on, you know, new digital tools, on e-tendering, amongst others, that we, kicked off in Q4 for the 2025 procurement round. That's another big initiatives. And, and last but not least, we are looking at, pricing as well, also in terms of indeed, how differentiated, you know, can we go by product line portfolio, slash, you know, BUs. So that's another one. Obviously, we are constantly looking at all the other fixed cost elements and primarily personnel costs as we go, making sure that we reallocate resources instead of adding. These are really the five major blocks that we are after, but in total, we are tracking with the transformation office 52 initiatives, you know, on that program, to compensate for the stranded costs. We've appointed a transformation leader that is part of the executive committee, reporting directly to me to track that on a bi-weekly basis. This is how we run the program. Super. Thanks for the color. Yeah. Okay. Our next question is from Reg Watson from ING. Reg, please go ahead. Thank you. Morning, all. Just to come back to Setu's question on the split of contracts in algae. I may have missed the answer, or it may have got lost in the sort of melee of several questions, but what was the split again, please, between spot, two-year, and three-year in terms of algae volume sales? That's my first sort of follow-up on Setu's, and then I've got some of my own. So if I, if I can take this one again, we don't give the exact number, but you know you can see that we have a good two set of business that is contracted longer term on our aquaculture business. The rest is more standard practice, yearly contracts. Okay, so you're not gonna tell us what the mix is, so we can't actually forecast when these- I mean- - contracts are gonna roll off? ... I think that would be competitively sensible, you know, if we would disclose more our contract positions, so which we're not keen to do well. Right. Okay, fair enough. Fair enough. And then, and then on to the gypsum-free lactic acid plant. Obviously, it's still in ramp-up at the moment. Can you give us any indication of what sort of utilization rates you're running at? How that's going versus plan? And then the third question, when you expect to be at full capacity? So we've been running, you know, this again, without going into too many technicals. We've been ramping up, you know, by sequence, you know, from 20%-40-ish% capacity occupation. And so we've been at that level. We've been also looking to optimization, which is part of our process, which we are doing currently right now. So, our aim then is, again, to ramp up really fully next year. Obviously, you know, the sooner the better, I have to say. Now, if I see the level of reliability that is important for us, you know, getting to, as you know, in this type of plant, you know, at 70-80% capacity occupation, in theory, you know, what we're gonna aim for, to make sure that we ramp up in a reliable way. So that's the plan for next year. Okay. That's really helpful. Thank you. And then just finally to circle back on Ferdinand's question about, you know, cash flow and EBITDA guidance going up, but leverage guidance going down. You knew at the half year, Peter, that the share buyback, the special dividend, and the increased ordinary dividend, were all going to have this impact on your debt levels. You didn't know at the half year that you were gonna have a blowout Q3. So why did you decide not to adjust the guidance at the first half, but you have decided to adjust the guidance now? I mean, if you look overall, then we indeed did not adjust it during the half year one, because the reality is we were spot on in this, these items, which we are also now. We tightened it based on where we currently are, because it makes no sense to have a much wider range following all the other updates we did. Right. Okay. Okay, no, that's really helpful. Thank you. Appreciate it. Okay, and that, that's it for questions, today. Olivier, did you want to make some, closing remarks? No, first of all, I'd like to thank everyone, I mean, to join, you know, this call. And basically, we will revert back to you early next year for the full year results. So thank you really for joining us today. Wish you, I mean, a good end of the year, and, yeah, speak early next year to all of you. Thank you. Operator, you may end the call. Thank you. Thank you. This concludes the Corbion Q3 Results 2024 on October 29, 2024. Thank you for listening. You may now disconnect.